JP4585448B2 - 第Xa因子阻害剤としてのピラゾール−誘導体 - Google Patents

第Xa因子阻害剤としてのピラゾール−誘導体 Download PDF

Info

Publication number
JP4585448B2
JP4585448B2 JP2005502535A JP2005502535A JP4585448B2 JP 4585448 B2 JP4585448 B2 JP 4585448B2 JP 2005502535 A JP2005502535 A JP 2005502535A JP 2005502535 A JP2005502535 A JP 2005502535A JP 4585448 B2 JP4585448 B2 JP 4585448B2
Authority
JP
Japan
Prior art keywords
thiophen
chloro
ylmethyl
isopropyl
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005502535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511608A (ja
JP2006511608A5 (enExample
Inventor
マルク・ナザレ
フォルクマール・ヴェーナー
デイヴィッド・ウィリアム・ウィル
ハンス・マター
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02028915A external-priority patent/EP1433788A1/en
Priority claimed from EP03011308A external-priority patent/EP1479678A1/en
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006511608A publication Critical patent/JP2006511608A/ja
Publication of JP2006511608A5 publication Critical patent/JP2006511608A5/ja
Application granted granted Critical
Publication of JP4585448B2 publication Critical patent/JP4585448B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2005502535A 2002-12-23 2003-12-10 第Xa因子阻害剤としてのピラゾール−誘導体 Expired - Fee Related JP4585448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028915A EP1433788A1 (en) 2002-12-23 2002-12-23 Pyrazole-derivatives as factor Xa inhibitors
EP03011308A EP1479678A1 (en) 2003-05-19 2003-05-19 Pyrazole-derivatives as factor xa inhibitors
PCT/EP2003/013979 WO2004056815A1 (en) 2002-12-23 2003-12-10 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (3)

Publication Number Publication Date
JP2006511608A JP2006511608A (ja) 2006-04-06
JP2006511608A5 JP2006511608A5 (enExample) 2007-01-11
JP4585448B2 true JP4585448B2 (ja) 2010-11-24

Family

ID=32683809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005502535A Expired - Fee Related JP4585448B2 (ja) 2002-12-23 2003-12-10 第Xa因子阻害剤としてのピラゾール−誘導体

Country Status (13)

Country Link
EP (1) EP1581523B1 (enExample)
JP (1) JP4585448B2 (enExample)
AR (1) AR042648A1 (enExample)
AT (1) ATE444292T1 (enExample)
AU (1) AU2003292218A1 (enExample)
BR (1) BR0317659A (enExample)
CA (1) CA2511321A1 (enExample)
DE (1) DE60329529D1 (enExample)
IL (1) IL169323A0 (enExample)
MX (1) MXPA05006200A (enExample)
PE (1) PE20040925A1 (enExample)
TW (1) TW200505914A (enExample)
WO (1) WO2004056815A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
JP4912314B2 (ja) 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Xa化合物
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101087762A (zh) * 2004-10-29 2007-12-12 先灵公司 作为抗病毒剂的取代的5-甲酰胺吡唑和[1,2,4]三唑
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
EP1724269A1 (en) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
WO2007002559A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
WO2009080227A2 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) * 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP5432890B2 (ja) 2008-04-04 2014-03-05 武田薬品工業株式会社 複素環誘導体及びその用途
EP2276761B1 (en) * 2008-04-23 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
AR079967A1 (es) 2010-01-26 2012-02-29 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
HRP20160047T1 (hr) 2011-07-26 2016-02-12 Sanofi Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova
BR112014001587A2 (pt) 2011-07-26 2017-02-14 Sanofi Sa derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos
WO2013072327A1 (en) 2011-11-14 2013-05-23 Sanofi Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
MX373964B (es) 2013-03-15 2020-07-13 Verseon Corp Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
AR095764A1 (es) 2013-03-28 2015-11-11 Sanofi Sa Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos
SG11201506292XA (en) 2013-03-28 2015-09-29 Sanofi Sa Biaryl-propionic acid derivatives and their use as pharmaceuticals
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
SI3261639T1 (sl) 2015-02-27 2023-01-31 Verseon International Corporation Substituirane pirazolne spojine kot zaviralci serinskih proteaz
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
NZ504013A (en) * 1997-11-28 2002-02-01 Lg Chemical Ltd Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
BR9813835A (pt) * 1997-12-22 2000-10-10 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
SI1140941T1 (en) * 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
ATE268766T1 (de) * 1999-07-16 2004-06-15 Bristol Myers Squibb Pharma Co Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
CA2385589A1 (en) * 1999-09-17 2001-03-22 Bing-Yan Zhu Inhibitors of factor xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1226123A1 (en) * 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyano compounds as factor xa inhibitors
AU2001268711A1 (en) * 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US6750225B2 (en) * 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors

Also Published As

Publication number Publication date
WO2004056815A1 (en) 2004-07-08
JP2006511608A (ja) 2006-04-06
BR0317659A (pt) 2005-12-06
ATE444292T1 (de) 2009-10-15
EP1581523B1 (en) 2009-09-30
TW200505914A (en) 2005-02-16
EP1581523A1 (en) 2005-10-05
AR042648A1 (es) 2005-06-29
DE60329529D1 (de) 2009-11-12
MXPA05006200A (es) 2005-08-19
CA2511321A1 (en) 2004-07-08
AU2003292218A1 (en) 2004-07-14
PE20040925A1 (es) 2004-12-24
IL169323A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
US7910606B2 (en) Pyrazole-derivatives as factor Xa inhibitors
JP4709763B2 (ja) 第Xa因子阻害剤としてのインダゾール誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
JP4608495B2 (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
AU2003285336B2 (en) Imidazole-derivatives as factor Xa inhibitors
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
US20040171604A1 (en) Imidazole derivatives as factor Xa inhibitors
JP4733642B2 (ja) 第Xa因子阻害剤としてのアザインドール−誘導体
EP1479678A1 (en) Pyrazole-derivatives as factor xa inhibitors
HK1089174B (en) Benzimidazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100810

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100903

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130910

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees